DFTX Phase 3 DT120 ODT 100 mcg meets GAD endpoints
A Phase 3 Panorama study in generalized anxiety disorder (GAD) reported that DT120 ODT 100 mcg met all primary and key secondary endpoints, with favorable safety and sustained efficacy in interim extension data (partial).
Story updates
12:14:02 PM UTC
SquawkNews
Definium Therapeutics announced positive Phase 3 Panorama topline results for DT120 ODT 100 µg, meeting the primary and all key secondary endpoints with a placebo—adjusted HAM—A improvement of 5.1 points at Week 12.Key Highlights:Original SEC Filing: Definium Therapeutics, Inc. [ DFTX ] - 8-K - Sep…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.